

5' Nucleotidase - Pipeline Review, H1 2020

https://marketpublishers.com/r/5319361D5624EN.html

Date: June 2020

Pages: 109

Price: US\$ 3,500.00 (Single User License)

ID: 5319361D5624EN

Abstracts

5' Nucleotidase - Pipeline Review, H1 2020

SUMMARY

According to the recently published report '5' Nucleotidase – Pipeline Review, H1 2020'; 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 34 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – 5?-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides.

The report '5' Nucleotidase – Pipeline Review, H1 2020' outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 16 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Solid



Tumor, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Melanoma, Triple-Negative Breast Cancer (TNBC), Breast Cancer, Colorectal Cancer, Kidney Cancer (Renal Cell Cancer), Prostate Cancer, Colon Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Lung Cancer, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Lung Cancer, Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)

The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects

The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type



The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contents

Introduction

- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Overview
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Therapeutics Development
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Therapeutics Assessment
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Companies Involved in Therapeutics Development
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Drug Profiles
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Dormant Products
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Product Development Milestones

Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1)

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Akeso Inc, H1 2020

Pipeline by Aprilbio Co Ltd, H1 2020

Pipeline by Arcus Biosciences Inc, H1 2020

Pipeline by AstraZeneca Plc, H1 2020

Pipeline by Aurigene Discovery Technologies Ltd, H1 2020

Pipeline by Bristol-Myers Squibb Co, H1 2020

Pipeline by Calithera Biosciences Inc, H1 2020

Pipeline by Corvus Pharmaceuticals Inc, H1 2020

Pipeline by Eli Lilly and Co, H1 2020

Pipeline by Eternity Bioscience Inc, H1 2020

Pipeline by Evotec SE, H1 2020

Pipeline by Gilead Sciences Inc, H1 2020

Pipeline by Harbour BioMed, H1 2020

Pipeline by I-Mab Biopharma Co Ltd, H1 2020

Pipeline by Innate Pharma SA, H1 2020

Pipeline by InteRNA Technologies BV, H1 2020

Pipeline by iOnctura SA, H1 2020

Pipeline by Merck & Co Inc, H1 2020

Pipeline by Novartis AG, H1 2020



Pipeline by ORIC Pharmaceuticals Inc, H1 2020

Pipeline by Phanes Therapeutics Inc, H1 2020

Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H1 2020

Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020

Pipeline by Shanghai Henlius Biotech Inc, H1 2020

Pipeline by Xcella Biosciences Inc, H1 2020

Dormant Projects, H1 2020



List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Akeso Inc

Aprilbio Co Ltd

Arcus Biosciences Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Corvus Pharmaceuticals Inc

Eli Lilly and Co

Eternity Bioscience Inc

Evotec SE

Gilead Sciences Inc

Harbour BioMed

I-Mab Biopharma Co Ltd

Innate Pharma SA

InteRNA Technologies BV

iOnctura SA

Merck & Co Inc.

Novartis AG

ORIC Pharmaceuticals Inc.

Phanes Therapeutics Inc

Secarna Pharmaceuticals GmbH & Co. KG

Shanghai De Novo Pharmatech Co Ltd

Shanghai Henlius Biotech Inc

Xcella Biosciences Inc



I would like to order

Product name: 5' Nucleotidase - Pipeline Review, H1 2020

Product link: https://marketpublishers.com/r/5319361D5624EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/5319361D5624EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970